The Pharmaceutical Education and Research Institute, Inc. (PERI) is an independent not-for-profit 501(c)(3) organization dedicated to providing scientific and technical continuing education. All activities are open to anyone in the pharmaceutical, biotechnology, and medical device industry as well as in related organizations including academic institutions and governmental agencies [i.e., the Food and Drug Administration (FDA) and the National Institutes of Health (NIH)].
PERI’s sole activity is to provide quality education and training to the pharmaceutical, biotechnology, and medical product industry. PERI currently is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE).
PERI and APCR are working together to offer APCR members special discounts on PERI educational offerings. APCR members can save over $300, or the entire value of APCR membership, by taking a few PERI courses. View the course offerings below and take advantage of your APCR membership today.
Members, make sure you are logged in to access a special link for the APCR discount.
APCR members have two options for registering for PERI’s on-demand archive webinars
This series of six webinars covers the area of immune-oncology in the context of pharmacologic and immunologic background, specific agents now approved, and changing practices and outlook for the cancer patient.
This webinar is an overview of oncology from the perspective of the oncologist and the developer of cancer drugs and is intended for newcomers to the field.
This webinar focuses on the mechanisms by which tumors escape normal immune surveillance. We review the nature of tumor immune surveillance, the “ideal” response of the immune system to cancer, and mechanisms that tumors use to evade surveillance and generate a state of tolerance.
The explosive growth of monoclonal antibody products in the past five years requires understanding of their pharmacology and important clinical results. The first part of this session addresses with mAbs that act through ADCC, through growth-factor processes, as mAb-cytotoxin conjugates and as mAb-radioisotope conjugates. The second part covers mAbs that target tumor microenvironment, counteract tolerance mechanisms, or stimulate cell-mediated antitumor effects.
This webinar covers the three major categories of cytokines from a pharmacologic and clinical application perspective, and discusses important considerations in the clinical development and use of both preventive and therapeutic vaccines in oncology.
This webinar surveys small molecules used as drugs that target oncogene-related abnormalities in cancer cells. The content focuses on agents that have recently achieved regulatory approval based on clinical trial successes.
Biological therapeutic proteins require special considerations from a pharmacokinetic and pharmacodynamics perspective. Certain characteristics are shared by large polypeptides such as cytokines, but monoclonal antibodies present particular challenges based on immunogenicity, IgG recycling processes and target-mediated drug distribution.
This webinar covers the three major categories of cytokines from a pharmacologic and clinical application perspective, and discusses important considerations in the clinical development and use of both preventive and therapeutic vaccines in oncology.Writing US Prescribing Information: Top Challenges
This high-level overview reviews elements that people find most challenging when interpreting labeling regulations and developing package inserts, and provides useful tips to equip your team with the knowledge to take the pain out of writing package inserts.Safety Labeling: Typical Problems and Their Solutions
This webinar covers global safety principles, such as what to include in local and core labeling as an adverse reaction and how to deal with event cascades.Unwanted Immunogenicity of Biological Drugs
This webinar defines the basic principles and importance of unwanted immunogenicity of biological drug candidates. Discussion focuses on potential causes of immunogenicity, impact on safety and efficacy of anti-drug antibody development.The Science Behind FDA Drug Approval: Clinical Trial Designs, Endpoints, Verification, and Requirements for Hematology Oncology Drugs
This two-hour webinar identifies and explains major considerations in the development process leading to a successful outcome of approval in oncology-hematology.Project Management Archived Webinar Series
This three-part webinar series addresses the fundamentals of Project Management as it applies to the research-based biopharmaceutical industry.
This webinar discusses determining “how to” plan, the identification of deliverables and the activities needed to complete deliverables. A special focus will be on best practices within the biopharmaceutical industry.
This webinar discusses how teams are developed and managed, what obstacles a team can encounter during a project, and some tips for addressing these challenges.
This webinar discusses communication channels and how open and proactive communication can go a long way to ameliorating common problems.